News Releases :: Sutro Biopharma, Inc. (STRO)

Apr 29, 2022 5:00 pm EDT

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2022 1:00 pm EDT

Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

Apr 5, 2022 7:00 am EDT

Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference

Mar 30, 2022 4:05 pm EDT

Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC

Mar 3, 2022 7:00 am EST

Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference

Feb 28, 2022 4:35 pm EST

Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones

Jan 6, 2022 7:00 am EST

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Jan 5, 2022 4:30 pm EST

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

Dec 27, 2021 7:00 am EST

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

Dec 27, 2021 7:00 am EST

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer